Chondrogard, 100 mg/ml 2 ml 10 pcs

High-molecular-weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. It reduces degenerative changes in the cartilage of joints, accelerates the processes of its restoration, stimulates the synthesis of proteoglycans. Treatment with Hondrogard reduces pain and improves mobility of affected joints.

In the treatment of degenerative changes in joints with development of secondary synovitis positive effect can be observed within 2-3 weeks after the start of the drug administration: pain in the joints reduces, clinical manifestations of reactive synovitis disappear and the range of motion in the affected joints increases.

Therapeutic effect of Hondrogard lasts for a long time after the end of the course of treatment.

Indications

Degenerative-dystrophic diseases of the joints and spine:

osteoarthritis of peripheral joints;
intervertebral osteochondrosis and osteoarthrosis;
to accelerate the formation of callus in fractures.

Pharmacological effect

High molecular weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. Reduces degenerative changes in the cartilage tissue of joints, accelerates its restoration processes, stimulates the synthesis of proteoglycans. When treated with Chondroguard, pain decreases and mobility of the affected joints improves.

When treating degenerative changes in joints with the development of secondary synovitis, a positive effect can be observed within 2-3 weeks after the start of drug administration: joint pain decreases, clinical manifestations of reactive synovitis disappear, and range of motion in the affected joints increases.

The therapeutic effect of Chondrogard persists for a long time after the end of the course of treatment.

Special instructions

Use in pediatrics

There are currently no data on the effectiveness and safety of chondroitin sulfate in children.

Active ingredient

Chondroitin sulfate

Composition

Active ingredient:

chondroitin sulfate sodium – 100 mg.

Excipients:

benzyl alcohol – 9 mg,

sodium disulfite – 1 mg,

sodium hydroxide – up to pH 6.0-7.5,

water for d/i – up to 1 ml.

Pregnancy

Contraindicated during pregnancy and breastfeeding

Contraindications

Hypersensitivity to the drug or its components;
bleeding and tendency to bleed;
thrombophlebitis;
childhood;
pregnancy and lactation (data on the safety of the drug are currently not available).

Side Effects

Allergic reactions: skin itching, erythema, urticaria, dermatitis, hemorrhages at the injection site.

Interaction

The effect of indirect anticoagulants, antiplatelet agents, and fibrinolytics may be enhanced, which requires more frequent monitoring of blood coagulation parameters when used together.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

PharmFirma Sotex, Russia